Hospital
Sutter Bay Hospitals
Sutter Bay Hospitals was paid $14.94M by Medicaid between Jan 2018 and Dec 2024, across 198 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 14% of everything it billed.
33Billing provider infoSUTTER BAY HOSPITALS
SAN FRANCISCO, CA 94110
SAN FRANCISCO, CA 94110
33aNPI1730238007assigned 01/09/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.94M
24GClaims325,183
24DCodes billed198
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#151 of 410
Median peer was paid$6.90M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GATES, JOHN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,093 | $1.31M | |
| 2019 | 41,260 | $1.25M | |
| 2020 | 45,273 | $1.57M | |
| 2021 | 46,612 | $2.23M | |
| 2022 | 47,613 | $2.69M | |
| 2023 | 56,733 | $3.53M | |
| 2024incomplete | 44,599 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 14% | 28,875 | 25,216 | $2.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.7% | 2,989 | 2,649 | $1.31M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 977 | 934 | $1.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.7% | 2,379 | 2,317 | $995K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.8% | 7,051 | 6,651 | $873K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.4% | 3,254 | 3,112 | $809K |
| 0450 | Emergency room services | 4.7% | 13,916 | 12,661 | $698K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.6% | 5,626 | 5,297 | $541K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.9% | 1,661 | 1,505 | $439K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.6% | 1,708 | 1,682 | $382K |
| 99199 | Unlisted special service, procedure or report | 2.3% | 3,096 | 2,674 | $344K |
| 80053 | Comprehensive metabolic panel | 2.2% | 21,093 | 19,702 | $325K |
186 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 4,293 | $312K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 4,008 | $302K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 8,398 | $298K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 1,558 | $253K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 1,201 | $237K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 1.5% | 14,344 | $230K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 6,048 | $221K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 23,827 | $217K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 3,725 | $214K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 779 | $188K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,037 | $182K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,435 | $144K |
| 82077 | <1% | 2,735 | $127K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,482 | $125K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,457 | $124K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,539 | $112K |
| 83880 | <1% | 1,916 | $89K | |
| 84484 | <1% | 6,117 | $80K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,439 | $78K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 190 | $69K |
| 83690 | <1% | 7,173 | $65K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,542 | $55K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,518 | $53K |
| J3490 | Unclassified drugs | <1% | 3,324 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,208 | $46K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,066 | $40K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,473 | $38K |
| 80061 | Lipid panel | <1% | 4,669 | $33K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,684 | $33K |
| 80143 | <1% | 403 | $30K | |
| 81025 | <1% | 4,945 | $30K | |
| 0270 | <1% | 1,086 | $29K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 415 | $29K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,579 | $29K |
| 81001 | <1% | 7,410 | $28K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 727 | $28K |
| 87040 | <1% | 1,496 | $27K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,732 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 940 | $24K |
| 94060 | <1% | 170 | $23K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,050 | $23K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 293 | $23K |
| 83605 | <1% | 1,555 | $21K | |
| 83735 | <1% | 2,093 | $20K | |
| 80179 | <1% | 405 | $19K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,436 | $18K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 179 | $17K |
| 84702 | <1% | 2,186 | $17K | |
| 76830 | Ultrasound, transvaginal | <1% | 264 | $16K |
| 73030 | <1% | 355 | $16K | |
| 94726 | <1% | 213 | $16K | |
| 73610 | <1% | 486 | $16K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 41 | $15K |
| 81003 | <1% | 4,730 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,917 | $12K |
| 85610 | <1% | 2,604 | $12K | |
| 87081 | <1% | 1,302 | $12K | |
| 87186 | <1% | 1,309 | $11K | |
| 73630 | <1% | 356 | $11K | |
| 94729 | <1% | 213 | $11K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 114 | $10K |
| 85730 | <1% | 1,479 | $10K | |
| 85027 | <1% | 1,629 | $9K | |
| 83789 | <1% | 478 | $9K | |
| 80055 | <1% | 291 | $9K | |
| 87400 | <1% | 1,638 | $9K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 931 | $9K |
| 87430 | <1% | 807 | $8K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 86 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 813 | $8K |
| 93797 | <1% | 114 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 651 | $8K |
| 82947 | <1% | 1,046 | $8K | |
| 73564 | <1% | 220 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 641 | $8K |
| 85379 | <1% | 483 | $7K | |
| 0250 | <1% | 357 | $7K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 20 | $7K |
| 93971 | <1% | 25 | $7K | |
| 73130 | <1% | 100 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 73 | $7K |
| 83970 | <1% | 92 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 79 | $6K |
| 70496 | <1% | 13 | $6K | |
| 82728 | <1% | 905 | $6K | |
| 86481 | <1% | 165 | $5K | |
| 86803 | <1% | 839 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 548 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 271 | $5K |
| 84439 | <1% | 739 | $4K | |
| 82805 | <1% | 96 | $4K | |
| 82570 | <1% | 1,185 | $4K | |
| 73562 | <1% | 75 | $4K | |
| 99070 | <1% | 976 | $3K | |
| 82043 | <1% | 809 | $3K | |
| 86592 | <1% | 1,345 | $3K | |
| 82951 | <1% | 245 | $3K | |
| 86787 | <1% | 238 | $3K | |
| 71271 | <1% | 79 | $2K | |
| 87077 | <1% | 278 | $2K | |
| 77080 | <1% | 13 | $2K | |
| 85652 | <1% | 968 | $2K | |
| 86901 | <1% | 510 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 614 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 25 | $2K |
| 83550 | <1% | 203 | $2K | |
| 90715 | <1% | 39 | $2K | |
| 83540 | <1% | 267 | $2K | |
| 87420 | <1% | 256 | $2K | |
| 86900 | <1% | 529 | $2K | |
| 82274 | <1% | 94 | $2K | |
| 73502 | <1% | 25 | $1K | |
| 71020 | <1% | 40 | $1K | |
| 86140 | <1% | 195 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $1K |
| 87634 | <1% | 20 | $1K | |
| 84550 | <1% | 189 | $1K | |
| 86850 | <1% | 179 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16 | $1K |
| 82607 | <1% | 106 | $1K | |
| 84100 | <1% | 200 | $1K | |
| 87486 | <1% | 21 | $1K | |
| 87581 | <1% | 21 | $1K | |
| 86480 | <1% | 13 | $997.83 | |
| 0272 | <1% | 45 | $996.74 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 41 | $956.43 |
| 71010 | <1% | 65 | $886.33 | |
| 82550 | <1% | 110 | $838.06 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 28 | $614.52 |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,849 | $605.51 |
| 86038 | <1% | 89 | $583.86 | |
| 84153 | <1% | 27 | $577.90 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 92 | $568.40 |
| 72100 | <1% | 14 | $542.59 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 70 | $521.59 |
| 84436 | <1% | 203 | $434.81 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 57 | $403.46 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 28 | $393.97 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 44 | $393.30 |
| 87340 | <1% | 96 | $379.53 | |
| 80076 | <1% | 63 | $329.03 | |
| 85045 | <1% | 57 | $311.88 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 789 | $269.29 |
| 87147 | <1% | 57 | $228.22 | |
| 83021 | <1% | 42 | $218.35 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 12 | $179.94 |
| 87210 | <1% | 41 | $154.79 | |
| 82746 | <1% | 18 | $145.55 | |
| 87088 | <1% | 27 | $141.94 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 14 | $133.11 |
| 84460 | <1% | 43 | $132.37 | |
| 82652 | <1% | 12 | $129.16 | |
| 86706 | <1% | 14 | $72.41 | |
| 83655 | <1% | 110 | $59.97 | |
| 86431 | <1% | 12 | $57.84 | |
| 99441 | 0% | 52 | $0.00 | |
| 90686 | 0% | 809 | $0.00 | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | 0% | 267 | $0.00 |
| 92551 | 0% | 792 | $0.00 | |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 2,125 | $0.00 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 196 | $0.00 |
| 0250R | 0% | 13 | $0.00 | |
| 90688 | 0% | 75 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 28 | $0.00 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 12 | $0.00 |
| G9012 | Other specified case management service not elsewhere classified | 0% | 21 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 16 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 15 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 34 | $0.00 |
| 85018 | 0% | 75 | $0.00 | |
| 90698 | 0% | 12 | $0.00 | |
| 59426 | 0% | 1,972 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 89 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 515 | $0.00 |
| 99173 | 0% | 723 | $0.00 | |
| H1003 | Prenatal care, at-risk enhanced service; education | 0% | 1,409 | $0.00 |
| 90461 | 0% | 270 | $0.00 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 0% | 330 | $0.00 |
| 99401 | 0% | 128 | $0.00 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 0% | 256 | $0.00 |
| 90633 | 0% | 38 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 13 | $0.00 |
| 99442 | 0% | 278 | $0.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 84 | $0.00 |
| 90670 | 0% | 80 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGATES, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sutter Bay Hospitals | Castro Valley, CA | $52.65M |
| Sutter Bay Hospitals | Oakland, CA | $46.80M |
| Sutter Bay Hospitals | Berkeley, CA | $43.78M |
| Sutter Bay Hospitals | Lakeport, CA | $39.50M |
| Sutter Bay Hospitals | Santa Rosa, CA | $35.23M |
| Sutter Bay Hospitals | Antioch, CA | $29.48M |
| Sutter Bay Hospitals | San Francisco, CA | $19.99M |
| Sutter Bay Hospitals | Burlingame, CA | $17.15M |
| Sutter Bay Hospitals | Novato, CA | $11.12M |
| Sutter Bay Hospitals | San Francisco, CA | $6.79M |
| Sutter Bay Hospitals | Lakeport, CA | $3.99M |
| Sutter East Bay Hospitals | Antioch, CA | $3.45M |
| Sutter Bay Hospitals | Burlingame, CA | $1.98M |
| Sutter Bay Hospitals | Lakeport, CA | $1.72M |
| Sutter East Bay Hospitals | Oakland, CA | $1.10M |
| Sutter Bay Hospitals | San Francisco, CA | $1.08M |
| Sutter East Bay Hospitals | Berkeley, CA | $946K |
| Sutter West Bay Hospitals | San Francisco, CA | $186K |
| Magnetic Imaging Affiliates, LLC | Oakland, CA | $112K |
| Sutter Bay Hospitals | Berkeley, CA | $45K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.